Equities

QLI

KYG7307E1070

Delayed Nasdaq Other stock markets 12:42:55 17/05/2024 am IST			5-day change	1st Jan Change
0.7499 ^USD	+8.67%		+2.70%	-11.80%

15/02	Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2023	CI
12/01	Qilian International Gets Nasdaq Extension to Meet Minimum Bid Price Rule; Shares Rise	MT

Qilian International Holding Group Limited Reports Earnings Results for the Half Year Ended March 31, 2022

September 01, 2022 at 02:30 am IST

Qilian International Holding Group Limited reported earnings results for the half year ended March 31, 2022. For the half year, the company reported sales was USD 32.09 million compared to USD 29.94 million a year ago. Net income was USD 0.087862 million compared to USD 2.35 million a year ago.

Latest news about QILN HLDG

Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2023	16/02	CI
Qilian International Gets Nasdaq Extension to Meet Minimum Bid Price Rule; Shares Rise	12/01	MT
Qilian International Holding Group Limited Reports Earnings Results for the Half Year Ended March 31, 2023	05/23/05	CI
Qilian International Holding Group Limited Announces Board Changes	26/23/26	CI
Qilian International Gets Noncompliance Notice From Nasdaq	17/23/17	MT
Qilian International Holding Group Limited Announces Board Changes	15/23/15	CI
Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2022	20/23/20	CI
Qilian International Holding Group Ltd Declares Special Cash Dividend, Payable on or About March 6, 2023	17/23/17	CI
Qilian International Holding Group Limited Reports Earnings Results for the Half Year Ended March 31, 2022	01/22/01	CI
Qilian International Earnings Drop to Breakeven in Latest Six-Month Reporting Period, Revenue Climbs 7%	01/22/01	MT
Qilian International Holding Group Limited Announces Board Changes	16/22/16	CI
Qilian International Holding Group Limited Intend in 2022 and Beyond to Complete the Construction of a Pig By-Product Processing Facility	12/22/12	CI
Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2021	12/22/12	CI
Qilian International Obtains Approval to Sell Nitrofurantoin Enteric-coated Tablets	19/22/19	MT
Qilian International Holding Group Limited Receives Approval for the Sale of Its Newly Developed Nitrofurantoin Enteric-Coated Tablets	19/22/19	CI
Qilian Subsidiary Developing Vitacoenzyme to Prevent Gastric Cancer	15/21/15	MT
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention	15/21/15	CI
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts it into Production	26/21/26	CI
Qilian International : Unit Wins Gansu Province OK to Export Oxytetracycline API to Egypt	13/21/13	MT
Qilian International Holding Group Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended March 31, 2021	17/21/17	CI
Certain Ordinary Shares of Qilian International Holding Group Limited are subject to a Lock-Up Agreement Ending on 12-JUL-2021.	12/21/12	CI
Qilian International : to Invest $84 Million Pig By-product Processing Project	09/21/09	MT
Qilian International : Enters Exclusive Agency Agreement With Henan Kangzhiyuan Pharmaceutical	05/21/05	MT
Qilian International : Edging Higher in Late Trade After FY20 EPS Slips to $0.17; Revenue Increases 9% Over Year-Ago Levels	12/21/12	MT
Qilian International Holding Group Limited Announces Consolidated Earnings Results for the Year Ended September 30, 2020	12/21/12	CI

Chart QILN HLDG

Duration

Period

More charts

Company Profile

Qilian International Holding Group Ltd is a China-based company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The Company operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. Its main brand is Qilian Shan. The Company principally operates its businesses within the domestic market.

Sector

More about the company

Income Statement Evolution

More financial data